Imjudo® (Tremelimumab) for Mesothelioma Treatment

Imjudo (Tremelimumab) for Mesothelioma Treatment | Side Effects
Licensed Under Creative Commons – Wikipedia

Imjudo® (Tremelimumab), a checkpoint inhibitor, harnesses the body’s own immune system to identify and combat cancer cells, offering a glimmer of hope for mesothelioma patients.

Imjudo, a checkpoint inhibitor belonging to the broader category of immunotherapy drugs, operates by unleashing the patient’s immune system to recognize and assail cancer cells. This innovative approach has already secured approval for specific liver and lung cancers, yet its journey in mesothelioma treatment is still in the realm of exploration.

How Imjudo (Tremelimumab) Takes on Mesothelioma

Imjudo functions as an immunotherapy drug that galvanizes the immune system’s cancer-fighting abilities. As a checkpoint inhibitor, Imjudo is a monoclonal antibody treatment with immense potential. It interferes with immune checkpoints, the mechanisms cancer cells employ to evade the immune system’s radar.

T cells, the immune system’s warriors, can identify and destroy harmful entities in the body. However, immune checkpoints act as safeguards, preventing T cells from mistakenly targeting healthy cells. Cancer cells exploit these checkpoints to avoid immune detection. Imjudo disrupts one such checkpoint called CTLA-4, thwarting cancer cells’ evasion tactics.

Early studies suggest that when combined with Imfinzi® (durvalumab), another checkpoint inhibitor targeting different checkpoints, Imjudo holds promise in mesothelioma treatment, mirroring the actions of FDA-approved inhibitors like Yervoy® and Opdivo®.

Imjudo (Tremelimumab) in Clinical Studies

Imjudo’s role in mesothelioma treatment remains experimental, devoid of a standardized treatment protocol. Clinical trials have explored its use in patients with inoperable pleural or peritoneal mesothelioma, administered alongside Imfinzi in distinct phases. These studies aim to uncover novel ways to integrate Imjudo into mesothelioma therapy.

The Benefits and Side Effects

The potential advantages of Imjudo in mesothelioma treatment are a beacon of hope. Early research offers glimpses into its efficacy, notably as a second-line treatment. Patients subjected to Imjudo and Imfinzi exhibited improved survival rates compared to traditional chemotherapy.

As with any medical intervention, Imjudo comes with potential side effects, including anemia, diarrhea, itching, and more. Additionally, patients undergoing Imjudo treatment may experience immune-related adverse events (irAEs), necessitating close monitoring and management.

Imjudo Eligibility

Imjudo’s official approval for mesothelioma treatment awaits further research, and eligibility criteria remain subject to ongoing investigation. Clinical trials incorporating Imjudo may impose specific prerequisites, considering factors like performance status, organ functionality, and life expectancy.

Research and Clinical Trials

While Imjudo has garnered approval for certain cancers, its role in mesothelioma treatment continues to evolve. Clinical trials explore its potential as a standalone therapy for relapsed mesothelioma and its efficacy in prolonged survival when combined with Imfinzi.